Prenuvo.

What Prenuvo actually is

A scaled imaging-only practice — the largest and most polished whole-body MRI screening operation in North America. Twenty-one US clinics; pricing from $1,199 (focused) to $4,499 (whole-body, NYC). The proposition is unusually clean for this category: a single test, longitudinally comparable, with no treatment programme attached.

This narrowness is the strength and the limitation, in roughly equal measure.

The strength

Three things Prenuvo gets meaningfully right.

Conflict structure. As an imaging-only practice, Prenuvo’s financial incentive runs entirely to delivering scans well. There is no peptide protocol downstream, no membership upsell into treatments, no margin earned from finding more. The clinic that scans you does not benefit from any treatment that follows.

Scale. Twenty-one US locations means a Prenuvo scan is accessible at the cost of a long drive for most American readers. Compared to the international travel a YEARS or HLI day requires, this is meaningful.

Longitudinal data. The year-over-year comparison framework — two scans separated by twelve months and read against each other — is an asset that single-visit clinics structurally cannot offer.

The limitation — and the honest evidence question

Whole-body MRI for asymptomatic screening sits in evidence territory where the major radiological societies remain divided. The pro case: incidental findings of clinical significance are caught earlier in some patients than they would otherwise be. The con case: the population-level rate of false positives, the cascade of follow-up imaging and biopsies, the non-trivial anxiety cost, and the absence of randomised mortality data make population-wide screening recommendation premature.

This is the central question with Prenuvo, and the answer for any individual reader is genuinely contingent: family history, personal risk profile, existing physician relationship.

We rank Prenuvo’s evidence base modestly because the underlying science of opportunistic whole-body MRI screening is itself contested, not because Prenuvo is dishonest about it. The patient communication is, in our reading, more careful than the marketing copy.

What Prenuvo is not

Prenuvo is not a comprehensive longevity workup. There is no CPET-grade VO₂ max. No cardiac function imaging beyond what the MRI captures. No comprehensive cardiometabolic panel. No CGM. The lab panel is targeted, not comprehensive.

For the reader looking for the full diagnostic spread, Prenuvo is a component, not a destination. The right pairing, in our view, is a sharp outpatient longevity day (YEARS Core) plus an annual Prenuvo scan — at total cost meaningfully lower than the upper tiers and with the imaging done by a specialist who does it at scale.

The verdict

Recommended for the reader who specifically wants the imaging finding, with full understanding of the evidence and false-positive question. Not recommended as a substitute for a comprehensive longevity workup.

An imaging clinic that does not also sell treatments is structurally rare and worth crediting. Whether you want the imaging is the more important question.